JTCS Medtronic Endurant
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chachques, J. C.
Right arrow Articles by Carpentier, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chachques, J. C.
Right arrow Articles by Carpentier, A.
Related Collections
Right arrow Molecular biology

J Thorac Cardiovasc Surg 2002;123:583-584
© 2002 The American Association for Thoracic Surgery

Letters to the Editor

Reply

J. C. Chachques, MD, PhD, A. Carpentier, MD, PhD

Department of Cardiovascular Surgery
Broussais Hospital
96 rue Didot
Paris 75014, France

Reply to the Editor:

The prevalence of severe heart failure and the clear clinical limitations of conventional interventions have encouraged the development of new methods based on regenerating the pool of myocardial contractile cells. This approach is supported by recent advances in cellular and molecular biology. Historically, tissue regeneration techniques based in cell transplantation technology had been used for the treatment of hemopathies, diabetes mellitus (Langerhans islets), neurology (Huntington and Parkinson diseases, spinal cord regeneration), hepatology (implantation of hepatocytes as a bridge to liver transplantation), myology (transplantation of myoblasts in Duchenne dystrophy), and orthopedics (implantation of chondrocytes in knee articulations).

Left ventricular remodeling is a major cause of progressive heart failure and death after myocardial infarction. Although neoangiogenesis within the infarcted tissue is an integral component of the remodeling process, the capillary network is unable to support the greater demands of the hypertrophied myocardium, resulting in progressive loss of viable tissue, infarct extension, and fibrous replacement. Intramyocardial cell grafting aims at limiting the consequences of the loss of contractile function of damaged ventricles. Cellular cardiomyoplasty is particularly attractive for a number of reasons, foremost . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
J. C. Chachques, C. Acar, J. Herreros, J. C. Trainini, F. Prosper, N. D'Attellis, J.-N. Fabiani, and A. F. Carpentier
Cellular cardiomyoplasty: clinical application
Ann. Thorac. Surg., March 1, 2004; 77(3): 1121 - 1130.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The American Association for Thoracic Surgery.